{
    "startDate": "2021-01-01",
    "endDate": "2021-06-30",
    "year": "2021",
    "quarter": "Q2",
    "symbol": "LIFE",
    "data": {
        "bs": [
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 152000
            },
            {
                "label": "Total assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 48995000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -61000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 751000
            },
            {
                "label": "Noncontrolling interest in Pangu BioPharma Limited",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": -171000
            },
            {
                "label": "Available-for-sale investments",
                "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
                "unit": "usd",
                "value": 41869000
            },
            {
                "label": "Common stock, $0.001 par value per share; 42,500,000 and 21,425,000 authorized shares as of June 30, 2021 and December 31, 2020, respectively; issued and outstanding shares \u2013 16,307,370 (unaudited) and 11,018,954 as of June 30, 2021 and December 31, 2020, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 16000
            },
            {
                "label": "Total liabilities and stockholders\u2019 equity",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 48995000
            },
            {
                "label": "Other receivables",
                "concept": "OtherReceivablesNetCurrent",
                "unit": "usd",
                "value": 90000
            },
            {
                "label": "Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares \u2013 0 as of June 30, 2021 (unaudited) and December 31, 2020, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 40805000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 40805000
            },
            {
                "label": "Accrued expenses",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 4141000
            },
            {
                "label": "Right-of-use assets",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 1685000
            },
            {
                "label": "Total aTyr Pharma stockholders\u2019 equity",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 40976000
            },
            {
                "label": "Prepaid expenses",
                "concept": "PrepaidExpenseCurrent",
                "unit": "usd",
                "value": 2256000
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 2192000
            },
            {
                "label": "Total current assets",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 46407000
            },
            {
                "label": "Commitments and contingencies (Note 4)",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapital",
                "unit": "usd",
                "value": 397091000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -356070000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -356100000.0
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 2224000
            },
            {
                "label": "Total current liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 7284000
            },
            {
                "label": "Current portion of operating lease liability",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 919000
            },
            {
                "label": "Current portion of operating lease liability",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 919000
            },
            {
                "label": "Long-term operating lease liability, net of current portion",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 906000
            },
            {
                "label": "Long-term operating lease liability, net of current portion",
                "concept": "OperatingLeaseLiabilityNoncurrent",
                "unit": "usd",
                "value": 906000
            }
        ],
        "cf": [
            {
                "label": "Net cash used in operating activities",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -13519000
            },
            {
                "label": "Maturities of available-for-sale investment securities",
                "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
                "unit": "usd",
                "value": 12768000
            },
            {
                "label": "Stock-based compensation",
                "concept": "AllocatedShareBasedCompensationExpense",
                "unit": "usd",
                "value": 758000
            },
            {
                "label": "Stock-based compensation",
                "concept": "AllocatedShareBasedCompensationExpense",
                "unit": "usd",
                "value": 758000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Proceeds from issuance of common stock through option exercises",
                "concept": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
                "unit": "usd",
                "value": 1000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationDepletionAndAmortization",
                "unit": "usd",
                "value": 244000
            },
            {
                "label": "Accretion of discount of available-for-sale investment securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -106000
            },
            {
                "label": "Amortization of right-of-use assets",
                "concept": "life:OperatingLeaseRightOfUseAssetAmortization",
                "unit": "usd",
                "value": 411000
            },
            {
                "label": "Net cash provided by financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 26128000
            },
            {
                "label": "Proceeds from issuance of common stock from committed purchase agreement, net of offering costs",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 15236000
            },
            {
                "label": "Operating lease liability",
                "concept": "life:IncreaseDecreaseInOperatingLeaseLiability",
                "unit": "usd",
                "value": -414000
            },
            {
                "label": "Prepaid expenses and other assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 405000
            },
            {
                "label": "Purchases of available-for-sale investment securities",
                "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
                "unit": "usd",
                "value": 40024000
            },
            {
                "label": "Other receivables",
                "concept": "IncreaseDecreaseInOtherReceivables",
                "unit": "usd",
                "value": -1949000
            },
            {
                "label": "Net change in cash and cash equivalents",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": -14760000
            },
            {
                "label": "Accounts payable and accrued expenses",
                "concept": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
                "unit": "usd",
                "value": 1379000
            },
            {
                "label": "Proceeds from issuance of common stock through employee stock purchase plan",
                "concept": "life:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
                "unit": "usd",
                "value": 5000
            },
            {
                "label": "Net cash provided by (used in) investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -27369000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 113000
            },
            {
                "label": "Proceeds from issuance of common stock from at the market offerings, net of offering costs",
                "concept": "life:ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts",
                "unit": "usd",
                "value": 10886000
            }
        ],
        "ic": [
            {
                "label": "Shares used in computing basic net loss per share, basic and diluted",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 15121721
            },
            {
                "label": "Net loss per share, basic and diluted",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -1.16
            },
            {
                "label": "Net loss attributable to aTyr Pharma, Inc.",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -17542000
            },
            {
                "label": "Net loss attributable to aTyr Pharma, Inc.",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -17500000.0
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 5476000
            },
            {
                "label": "Total other income (expense), net",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 100000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -17647000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 17647000
            },
            {
                "label": "Net loss attributable to noncontrolling interest in Pangu BioPharma Limited",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -5000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 12171000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -17565000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Consolidated net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -17547000
            },
            {
                "label": "Comprehensive loss attributable to noncontrolling interest Pangu BioPharma Limited",
                "concept": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -5000
            },
            {
                "label": "Change in unrealized gain (loss) on available-for-sale investments, net of tax",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -18000
            },
            {
                "label": "Comprehensive loss attributable to aTyr Pharma, Inc. common stockholders",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -17560000
            }
        ]
    }
}